Listen to the interview of Dr. Neil Baum share his top five places to eat and attractions you won't want to miss out on while attending the 2015 AUA annual meeting.

Audio Interview Of Dr. Neil Baum New Orleans Style 2015

William F. Gee, MD, who began his term as AUA president in May 2015, discusses current challenges facing the AUA and its members, possible solutions, and novel new AUA initiatives. 

Q&A with AUA President Dr. Gee

David F. Penson, MD, MPH, chair of the AUA Public Policy & Practice Support Council, answers questions about the Affordable Care Act and outcomes, some unique aspects of the ACA that pertain to urology, and more.


Q&A with David F. Penson, MD, MPH

Dr. Choyke was interviewed by Urology Times Editorial Consultant J. Brantley Thrasher, MD, professor and chair of urology at the University of Kansas Medical Center, Kansas City.  listen and learn as they discuss  how newer imaging techniques are rapidly changing how recurrent prostate cancer is managed.

Q & A with Peter L. Choyke, MD

Although prostate cancer may exhibit no symptoms in its early stages, symptoms like severe or unexplained pain, difficulty walking or climbing stairs, difficulty sleeping, or loss of bladder control may emerge when the disease advances. However, an international Harris Poll survey of over 1,200 people affected by the disease reveals nearly half of men (47%) sometimes ignore their symptoms. Hear from Neal Shore, MD, as he discusses with Crystal Murcia, PhD the surveys findings, explains why men aren’t speaking up about their symptoms, and urologists' role in assessing how patients are feeling.

Advanced prostate cancer: Why men aren’t speaking up

Michael Bailey, PhD, discusses novel ultrasound-based techniques for propelling and breaking kidney stones.

Q&A with Michael Bailey, PhD

While a number of medical and non-medical therapies are available to treat overactive bladder, underactive bladder, bladder outlet obstruction, and bladder pain syndrome, the search continues for therapeutic options that raise the bar of efficacy and safety. In this interview, Karl-Erik Andersson, MD, PhD, discusses current treatments for these common voiding dysfunctions and future directions, including central nervous system agents and combination therapies. Dr. Andersson is professor of urology at Wake Forest School of Medicine, Winston-Salem, NC. He is also a Jens Christian Skou fellow at Aarhus University, Aarhus, Denmark.

Dr. Andersson was interviewed by Urology Times Editorial Consultant Philip M. Hanno, MD, MPH, professor of urology at the University of Pennsylvania, Philadelphia.


CNS may be path to future voiding dysfunction therapies

The role of biopsy in renal masses is evolving. For large renal masses in particular, new data suggest biopsy may change the management of patients with certain high-risk features, according to E. Jason Abel, MD, assistant professor of urology at the University of Wisconsin School of Medicine and Public Health Madison. Dr. Abel discusses biopsy’s role in small and large renal masses, associated risks, and when patients can be safely observed.
Dr. Abel was interviewed by Urology Times Editorial Consultant J. Brantley Thrasher, MD, professor and chair of urology at the University of Kansas Medical Center, Kansas City.


Renal biopsy may alter management in high-risk patients

In this interview, Michael Wong, MD, describes difficult stones, discusses the skills and training required to treat them, and outlines the role of different treatment modalities. He was interviewed by Urology Times Editorial Consultant Stephen Y. Nakada, MD.


Difficult stones present treatment, training challenges

Sanofi Pasteur recently announced that it is discontinuing its BCG products TheraCys and ImmuCyst, prompting fears of a shortage of BCG for bladder cancer patients. In this interview, Dr. Benjamin J. Davies, associate professor of urology at the University of Pittsburgh School of Medicine, discusses the implications of the announcement and what’s next for patients and clinicians.